JPWO2022113799A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022113799A5
JPWO2022113799A5 JP2022565237A JP2022565237A JPWO2022113799A5 JP WO2022113799 A5 JPWO2022113799 A5 JP WO2022113799A5 JP 2022565237 A JP2022565237 A JP 2022565237A JP 2022565237 A JP2022565237 A JP 2022565237A JP WO2022113799 A5 JPWO2022113799 A5 JP WO2022113799A5
Authority
JP
Japan
Prior art keywords
tdp
intron
mrna
test substance
splicing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022565237A
Other languages
English (en)
Japanese (ja)
Other versions
JP7824653B2 (ja
JPWO2022113799A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/041895 external-priority patent/WO2022113799A1/ja
Publication of JPWO2022113799A1 publication Critical patent/JPWO2022113799A1/ja
Publication of JPWO2022113799A5 publication Critical patent/JPWO2022113799A5/ja
Application granted granted Critical
Publication of JP7824653B2 publication Critical patent/JP7824653B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022565237A 2020-11-30 2021-11-15 アンチセンス核酸及びその使用 Active JP7824653B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020198595 2020-11-30
JP2020198595 2020-11-30
PCT/JP2021/041895 WO2022113799A1 (ja) 2020-11-30 2021-11-15 アンチセンス核酸及びその使用

Publications (3)

Publication Number Publication Date
JPWO2022113799A1 JPWO2022113799A1 (https=) 2022-06-02
JPWO2022113799A5 true JPWO2022113799A5 (https=) 2023-10-23
JP7824653B2 JP7824653B2 (ja) 2026-03-05

Family

ID=81755982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565237A Active JP7824653B2 (ja) 2020-11-30 2021-11-15 アンチセンス核酸及びその使用

Country Status (4)

Country Link
US (1) US12584133B2 (https=)
EP (1) EP4253540A4 (https=)
JP (1) JP7824653B2 (https=)
WO (1) WO2022113799A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025234407A1 (ja) * 2024-05-08 2025-11-13 国立大学法人新潟大学 アンチセンス核酸及びその使用
WO2026009728A1 (ja) * 2024-07-03 2026-01-08 国立大学法人新潟大学 アンチセンス核酸及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272955B1 (en) 2008-04-09 2015-08-26 Tokyo Metropolitan Institute of Medical Science Tdp-43-storing cell model
WO2012150960A1 (en) * 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
ITRM20110582A1 (it) 2011-11-05 2013-05-06 Biotechnology Icgeb Modello cellulare per la selezione di molecole che influenzano l aggregazione di tdp-43
US11028390B2 (en) 2017-07-10 2021-06-08 Osaka University Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof
JP2020535802A (ja) * 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
JP2020198595A (ja) 2019-06-05 2020-12-10 株式会社フジクラ モード変換器

Similar Documents

Publication Publication Date Title
CA3213299A1 (en) Compositions and methods for targeted delivery to cells
US20240035011A1 (en) Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US20210207140A1 (en) Non-liposomal systems for nucleic acid delivery
JP7214915B2 (ja) Ｐｃｓｋ９遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP5766188B2 (ja) 固形腫瘍に治療剤を送達するための脂質製剤
Manahan-Vaughan et al. The metabotropic glutamate receptor, mGluR5, is a key determinant of good and bad spatial learning performance and hippocampal synaptic plasticity
US10415037B2 (en) Compositions and methods for silencing hepatitis B virus gene expression
JP7150608B2 (ja) 多量体コード核酸及びその使用
US8007790B2 (en) Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
Fox et al. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
US20180245074A1 (en) Treating hepatitis b virus infection using crispr
JPWO2022113799A5 (https=)
JP2025019119A (ja) ケイ素を含有するカチオン性脂質
AR086344A1 (es) Metodos de tratamiento o prevencion de trastornos relacionados con el colesterol
TW201718856A (zh) 用於使b型肝炎病毒基因表現沈默之組合物及方法
US20250304949A1 (en) Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
US20240065982A1 (en) Lipid nanoparticles for delivering therapeutics to lungs
Dong et al. Inhalable siRNA targeting IL-11 nanoparticles significantly inhibit bleomycin-induced pulmonary fibrosis
US8455455B1 (en) Compositions and methods for silencing genes involved in hemorrhagic fever
TW201920687A (zh) 用於治療b型肝炎感染之方法
TW202539707A (zh) 用於治療ｂ型肝炎之治療組成物及方法
JP2020526515A5 (https=)
MY145329A (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
US7888005B2 (en) Inhibitors of macromolecular activity
ES2427244T3 (es) Composición farmacéutica con contenido en una L-ribozima para el tratamiento de efectos secundarios mediante la administración de espiegelmeros